HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Thrombopoietin (c-mpl Ligand)

Subscribe to New Research on Thrombopoietin

A humoral factor that stimulates the production of thrombocytes (BLOOD PLATELETS). Thrombopoietin stimulates the proliferation of bone marrow MEGAKARYOCYTES and their release of blood platelets. The process is called THROMBOPOIESIS.

Also Known As:

c-mpl Ligand; MGDF Factor; Megakaryocyte Colony Stimulating Factor; Myeloproliferative Leukemia Virus Oncogene Ligand; Thrombocytopoiesis-Stimulating Factor; Thrombocytopoietin; mpl Ligand; Ligand, c-mpl; Ligand, mpl; Thrombocytopoiesis Stimulating Factor; Megakaryocyte Growth and Development Factor

Networked: 782 relevant articles (37 outcomes, 103 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Vainchenker, William: 9 articles (09/2014 - 11/2002)
2.	Miyazaki, Hiroshi: 9 articles (02/2008 - 03/2002)
3.	Kaushansky, Kenneth: 8 articles (01/2015 - 01/2003)
4.	Kato, T: 8 articles (12/2001 - 01/2000)
5.	Kuter, David J: 7 articles (04/2015 - 02/2008)
6.	Giraudier, Stéphane: 7 articles (09/2014 - 11/2002)
7.	Tulliez, Micheline: 6 articles (01/2011 - 11/2002)
8.	Ikeda, Yasuo: 6 articles (10/2008 - 08/2002)
9.	Murata, Soichiro: 5 articles (02/2014 - 11/2008)
10.	Ohkohchi, Nobuhiro: 5 articles (02/2014 - 11/2008)

Related Diseases

1.	Thrombocytopenia (Thrombopenia) 04/01/2000 - "Identification of TPO, the c-Mpl ligand, as the primary physiologic regulator of megakaryocyte and platelet development offers important promise for treatment of thrombocytopenia. " 09/01/2001 - "Therefore, when transfused into patients with thrombocytopenia, platelets collected from healthy donors undergoing thrombopoietin therapy were safe and resulted in significantly greater platelet count increments and longer transfusion-free intervals than platelets obtained from donors treated with placebo." 01/01/2012 - "However, recent disclosure that an oral thrombopoietin mimetic is effective in increasing platelet count in patients with MYH9-related thrombocytopenia opened new therapeutic perspectives. " 05/01/1995 - "Thrombopoietin also accelerates the recovery of platelets in myelosuppressed animals, suggesting that it will be clinically useful for the treatment of thrombocytopenia." 01/01/2012 - "We report an extended study of 23 pediatric and adult patients suffering from thrombocytopenia with absent radii syndrome in order to scrutinize thrombopoietin signal transduction by immunoblotting and gel electrophoretic shift assays. "
2.	Neoplasms (Cancer) 10/01/2012 - "Immunological assays and Luminex microarray revealed that tumor growth remission is mainly via natural killer cell (NK) reactivity and cross-regulation of IGF-binding protein-3, IGF/IGF-receptor, and megakaryocyte growth and development factor autocrine and paracrine loops. " 01/01/2011 - "Recombinant thrombopoietin (TPO) was used to expand MKs in the marrow and resulted in decreased skeletal lesion development after intracardiac tumor inoculation. " 01/01/2010 - "We have assessed high platelet count as a risk predictor for VTE in patients with cancer undergoing discriminative anti-cancer treatments and investigated whether platelet count correlates with thrombopoietin (TPO) levels. " 08/01/2003 - "Thrombopoietin-producing tumor." 03/01/1998 - "Thrombopoietin mobilizes CD34+ cell subsets into peripheral blood and expands multilineage progenitors in bone marrow of cancer patients with normal hematopoiesis."
3.	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 06/01/2013 - "In conclusion, increased plasma thrombopoietin levels were associated with a favorable prognosis of bone marrow failure and could, therefore, represent a reliable marker for a benign subset of myelodysplastic syndrome." 06/01/2013 - "Increased plasma thrombopoietin levels in patients with myelodysplastic syndrome: a reliable marker for a benign subset of bone marrow failure." 12/01/2002 - "To evaluate a potential therapeutic role for megakaryocyte growth and development factor (MGDF) in myelodysplastic syndromes (MDS) we compared the in vitro response of normal and myelodysplastic megakaryopoiesis to MGDF on bone marrow mononuclear cells from nine MDS patients and four healthy donors in a short term liquid culture system. " 10/01/2000 - "Colony-forming unit-megakaryocyte (CFR-meg) numbers and serum thrombopoietin concentrations in thrombocytopenic disorders: an inverse correlation in myelodysplastic syndromes." 08/01/2000 - "Thrombopoietin and myelodysplastic syndromes."
4.	Thrombocytosis (Thrombocythemia) 02/01/2002 - "These results indicate that plasma thrombopoietin levels may be helpful in distinguishing between clonal and reactive thrombocytosis." 05/01/1998 - "Thrombopoietin levels may be helpful in distinguishing between clonal thrombocytosis and reactive thrombocytosis. " 09/01/2004 - "The aims of this study were to evaluate the prevalence and clinical significance of thrombocytosis in HCC patients and its relationships with serum thrombopoietin (TPO). " 02/01/2002 - "The aim of this study is to assess circulating thrombopoietin concentrations in patients with both clonal and reactive thrombocytosis (RT), which are two distinct categories of extreme platelet production circumstances. " 12/01/1996 - "These results confirm the findings of two previous studies that thrombopoietin expression is not the main cause of thrombocytosis in the 3q21q26 syndrome."
5.	Liver Diseases (Liver Disease) 01/01/2015 - "Thrombopoietin (TPO) has been implicated in the process of liver regeneration and was found to correlate with hepatic function in patients with liver disease. " 01/01/2015 - "Deficiency in thrombopoietin induction after liver surgery is associated with postoperative liver dysfunction." 07/01/2008 - "Thrombopoietin level in patients with chronic liver diseases." 04/15/2006 - "The description of thrombopoietin and its (de)regulation in patients with chronic liver disease have disclosed new treatment opportunities. " 04/01/2004 - "However, serum thrombopoietin level decreased as liver disease aggravated, [(526.13+/-317.44) pg/ml in Child-Pugh grade A, (445.22+/-214.90) pg/ml in grade B and (311.45+/-182.66) pg/ml in grade C, grade A vs. Grade C, P<0.05]. "

Related Drugs and Biologics

1.	Inosine Triphosphate (ITP)
2.	Thrombopoietin (c-mpl Ligand)
3.	eltrombopag
4.	Carboplatin (JM8)
5.	polyethylene glycol-recombinant human megakaryocyte growth and development factor (PEG-MGDF)
6.	Granulocyte Colony-Stimulating Factor (G-CSF)
7.	romiplostim
8.	Polyethylene Glycols (Polyethylene Glycol)
9.	Erythropoietin
10.	Antibodies

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Bone Marrow Transplantation (Transplantation, Bone Marrow)
3.	Platelet Transfusion (Blood Platelet Transfusions)
4.	Liver Transplantation
5.	Transplantation (Transplant Recipients)